𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Degradation and clearance of methotrexate in children with osteosarcoma receiving high-dose infusion

✍ Scribed by Wang, Yeu-Ming ;Kim, Pyong-Young ;Lantin, Erlinda ;van Eys, D. Catherine ;Romsdahl, Marvin M. ;Sutow, Wataru W.


Publisher
John Wiley and Sons
Year
1978
Tongue
English
Weight
507 KB
Volume
4
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Plasma methotrexate (MTX) concentrations were quantitated in 34 patients after 127 high‐dose (35–350 mg/kg) infusions with citrovorum factor rescue. Significant linear correlations have been obtained between methotrexate dosage and concentrations in plasma at 6 and 24 hours after the initiation of the therapy. However, similar trends have not been observed when 48‐ and 72‐hour samples were analyzed. Clinical toxicity was not serious when the methotrexate level in plasma was < 4.5 Γ— 10^βˆ’6^ M at 48 hours after the start of a six‐hour infusion in children. A minimal four‐hour steady‐state methotrexate plasma level can be maintained during a six‐hour infusion. Children excrete methotrexate at a faster rate than adults; the half‐life of MTX during the first phase of plasma clearance curve is one hour shorter in children. Urinary analyses have indicated that substantial methotrexate is metabolized. The chemical nature of these components has not been identified. Further, the urinary metabolic profiles varied among patients.


πŸ“œ SIMILAR VOLUMES


High-dose methotrexate pharmacokinetics
✍ Kristine R. Crews; Tiebin Liu; Carlos Rodriguez-Galindo; Ming Tan; William H. Me πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 161 KB

## Abstract ## BACKGROUND High‐dose methotrexate (HDMTX) is used frequently in combination regimens that include nephrotoxic chemotherapy. The authors evaluated the impact of factors such as age and prior nephrotoxic agents on MTX pharmacokinetics in children and young adults with osteosarcoma and

Pharmacokinetic modeling of plasma and c
✍ E. Chatelut; H. Roche; Y. Plusquellec; F. Peyrille; J. De Biasi; A. Pujol; P. Ca πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 436 KB

A pharmacokinetic study was performed in plasma and cerebrospinal fluid (CSF) of patients suffering from brain tumors to describe the disposition of methotrexate. An open three-compartment model was developed to fit together the data obtained in plasma and CSF. The pharmacokinetic parameters obtaine

High-dose methotrexate-induced nephrotox
✍ Brigitte C. Widemann; Frank M. Balis; Beate Kempf-Bielack; Stefan Bielack; Charl πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 114 KB πŸ‘ 1 views

The authors thank Dr. James Balow at the National Institute of Diabetes, and Digestive, and Kidney Disorders for helpful suggestions during the preparation of this article. This article is dedicated to the memory of Dr. Charles Pratt, who devoted his extraordinary career to the treatment of children